- Home
- ALTO vs MGNX Comparison
ALTO vs MGNX Comparison
Compare ALTO & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALTO
- MGNX
- Stock Information
- Founded
- ALTO 2003
- MGNX 2000
- Country
- ALTO United States
- MGNX United States
- Employees
- ALTO N/A
- MGNX N/A
- Industry
- ALTO Major Chemicals
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- ALTO Industrials
- MGNX Health Care
- Exchange
- ALTO Nasdaq
- MGNX Nasdaq
- Market Cap
- ALTO 90.3M
- MGNX 87.7M
- IPO Year
- ALTO N/A
- MGNX 2013
- Fundamental
- Price
- ALTO $1.17
- MGNX $1.33
- Analyst Decision
- ALTO Strong Buy
- MGNX Hold
- Analyst Count
- ALTO 1
- MGNX 9
- Target Price
- ALTO $5.50
- MGNX $5.33
- AVG Volume (30 Days)
- ALTO 304.9K
- MGNX 2.0M
- Earning Date
- ALTO 08-05-2025
- MGNX 08-05-2025
- Dividend Yield
- ALTO N/A
- MGNX N/A
- EPS Growth
- ALTO N/A
- MGNX N/A
- EPS
- ALTO N/A
- MGNX N/A
- Revenue
- ALTO $951,169,000.00
- MGNX $154,050,000.00
- Revenue This Year
- ALTO N/A
- MGNX N/A
- Revenue Next Year
- ALTO $7.68
- MGNX N/A
- P/E Ratio
- ALTO N/A
- MGNX N/A
- Revenue Growth
- ALTO N/A
- MGNX 255.31
- 52 Week Low
- ALTO $0.76
- MGNX $0.99
- 52 Week High
- ALTO $2.05
- MGNX $5.77
- Technical
- Relative Strength Index (RSI)
- ALTO 63.88
- MGNX 41.45
- Support Level
- ALTO $0.86
- MGNX $1.33
- Resistance Level
- ALTO $1.27
- MGNX $2.17
- Average True Range (ATR)
- ALTO 0.08
- MGNX 0.17
- MACD
- ALTO 0.02
- MGNX -0.02
- Stochastic Oscillator
- ALTO 70.51
- MGNX 2.38
About ALTO Alto Ingredients Inc.
Alto Ingredients Inc is a producer of specialty alcohols and essential ingredients. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include major food and beverage companies and consumer products manufacturers and distributors. The company operates under three segments: Marketing and distribution, Pekin Campus production, Western production, and Others.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.